Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Blood safety and zoonotic emerging pathogens: now it's the turn of Zika virus!
Blood transfusion = Trasfusione del sangue·2015
Same author
Association between particulate air pollution and venous thromboembolism: A systematic literature review.
European journal of internal medicine·2015
Same author
Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres.
Seminars in thrombosis and hemostasis·2015
Related Experiment Video
Updated: Jul 16, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Thrombotic microangiopathies: an update.
1Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy. mfranchini@mail.univr.it
Hematology (Amsterdam, Netherlands)
|February 28, 2007
Summary
Thrombotic microangiopathies (TMA) involve microvascular blockages causing anemia and low platelets. This review details thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), focusing on diagnosis and treatment.
Area of Science:
- Hematology
- Vascular Medicine
- Pathophysiology
Background:
- Thrombotic microangiopathies (TMA) are a group of disorders characterized by microvascular occlusive events.
- Key features include microangiopathic hemolytic anemia, thrombocytopenia, and organ damage due to microthrombi.
- Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are primary TMAs with distinct clinical manifestations.
Purpose of the Study:
- To review the epidemiology and diagnostic criteria for TTP and HUS.
- To provide insights into the pathophysiology of these conditions.
- To discuss current and emerging treatment strategies for TTP and HUS.
Main Methods:
- Literature review of epidemiological data.
- Analysis of diagnostic criteria and clinical distinctions.
Main Results:
- TMA encompasses disorders like TTP (neurologic symptoms) and HUS (renal involvement).
- Distinguishing between TTP and HUS can be challenging despite characteristic features.
- Advances in understanding TMA pathophysiology are guiding new treatment approaches.
Conclusions:
- Accurate diagnosis and timely treatment are crucial for managing TTP and HUS.
- Continued research into TMA pathophysiology will likely yield improved therapeutic options.
- This review synthesizes current knowledge to aid clinicians in diagnosing and treating TMAs.